Last reviewed · How we verify
NCT03052062
Tolerance Study of the Dietary Supplement Lipidrive (ECPH1-03)
Phase 1, PHASE2 trial testing Lipidrive in Obese in 20 participants. Completed in 3 July 2018.
3 July 2018
Quick facts
| Lead sponsor | Valbiotis |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 2 March 2017 |
| Primary completion | 3 July 2018 |
| Estimated completion | 3 July 2018 |
| Sites | 1 location across France |
Drugs / interventions tested
- Lipidrive
Conditions studied
- Obese — all drugs for Obese →
Sponsor
Valbiotis
Who can join
Adults 45 to 65, male only, with Obese. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objectives of this clinical study are to determine the tolerance of dietary supplement Lipidrive through the evaluation of several parameters : * Various blood biological parameters * Urinary parameters * Hemodynamic indicators * Cardiac function * Anthropometric variables
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Poster abstracts
· 2018
Verify or expand the search:
- PubMed search for NCT03052062
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obese
Currently open trials in the same condition.
- NCT07411560 — A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in Peopl · Phase 1 · recruiting
- NCT06719466 — Diet Intervention on Obesity Related Complication · NA · active not recruiting
- NCT06590584 — Validity and Reliability of the 6-minute Pegboard Ring Test in Obese Individuals · recruiting
- NCT06562660 — The Effect of Mask Combined With High Flow Oxygen on Preoxygenation During Induction of General Anesthesia in Obese Pati · NA · recruiting
- NCT05819853 — Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome · Phase 3 · recruiting
Other Valbiotis trials
Trials by the same sponsor.
- NCT06243484 — Effect of the Food Supplement TOTUM-070 on Lipid Metabolism · NA · active not recruiting
- NCT06047847 — Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption · NA · completed
- NCT05594979 — Effects of 6 Weeks TOTUM-070 on Lipid Metabolism and Cardiovascular Health in Individuals at Increased Cardio-metabolic · NA · terminated
- NCT05469503 — Effect of TOTUM-854 on Blood Pressure in Subjects With Moderately Elevated Blood Pressure · NA · active not recruiting
- NCT05369585 — Mode of Action (MoA) Study of TOTUM-63 in Individuals at Increased Cardio-metabolic Risk · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03052062 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Valbiotis
- Last refreshed: 6 July 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03052062.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing